Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113194 - METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY

Publication Number WO/2020/113194
Publication Date 04.06.2020
International Application No. PCT/US2019/063889
International Filing Date 29.11.2019
IPC
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 2039/5158
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5158Antigen-pulsed cells, e.g. T-cells
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
Applicants
  • JUNO THERAPEUTICS, INC. [US]/[US]
Inventors
  • ALBERTSON, Tina
  • GARCIA, Jacob Randolph
  • GILBERT, Mark
  • LI, He
  • SUTHERLAND, Claire
Agents
  • AHN, Sejin
  • POTTER, Karen
Priority Data
62/774,16430.11.2018US
62/776,41506.12.2018US
62/847,92614.05.2019US
62/854,94530.05.2019US
62/890,60022.08.2019US
62/931,20405.11.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY
(FR) MÉTHODES POUR LE TRAITEMENT PAR THÉRAPIE CELLULAIRE ADOPTIVE
Abstract
(EN)
Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
(FR)
L'invention concerne une thérapie cellulaire adoptive qui implique l'administration de doses de cellules pour traiter des sujets atteints de maladies et de pathologies telles que certaines malignités de lymphocytes B, et des méthodes, des compositions, des utilisations et des articles manufacturés associés. Les cellules expriment généralement des récepteurs de recombinaison tels que des récepteurs antigéniques chimériques (CAR). Dans certains modes de réalisation, la maladie ou l'affection est un lymphome à grandes cellules B, tel qu'un lymphome diffus à grandes cellules B (DLBCL). L'invention concerne également des procédés d'évaluation du risque de développer une toxicité liée à une thérapie cellulaire, et des procédés d'identification de sujets et des méthodes de traitement de sujets sur la base de l'évaluation des risques.
Latest bibliographic data on file with the International Bureau